REGENXBIO Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ___ to ___Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) (240) 552-8181(Registrant’s telephone number, including area code)Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 8, 2026, there were 51,697,621 shares of the registrant’s common stock, par value $0.0001 per share, issued andoutstanding. REGENXBIO INC.QUARTERLY REPORT ON FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 TABLE OF CONTENTS PART I—FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)3Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended March31, 2026 and 20254Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and 20255Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures about Market Risk39Item 4.Controls and Procedures39 PART II—OTHER INFORMATION Item 1.Legal Proceedings40Item 1A.Risk Factors40Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities40Item 3.Defaults Upon Senior Securities40Item 4.Mine Safety Disclosures40Item 5.Other Information40Item 6.Exhibits41Signatures42 INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of theSecurities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (theExchange Act). These statements express a belief, expectation or intention and are generally accompanied by words that conveyprojected future events or outcomes such as “anticipate,” “assume,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,”“forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “position,” “potential,” “predict,” “project,” “seek,” “should,” “will,”“would” or variations of such words or by similar expressions. We have based these forward-looking statements on our currentexpectations, estimates and assumptions and analyses in light of our experience and our perception of historical trends, currentconditions and expected future developments, as well as other factors we believe are appropriate under the circumstances.However, whether actual results and developments will conform with our expectations and predictions is subject to a number ofrisks, uncertainties, assumptions and other important factors, including, but not limited to: •our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop andcommercialize surabgene lomparvovec (sura-vec, ABBV-RGX-314) and our collaboration with Nippon Shinyaku Co.,Ltd. to develop and commercialize RGX-121 (clemidsogene lanparvovec) and RGX-111;•our ability to obtain, including under accelerated approval, and mai